a Division of Hematology/Oncology , Tufts Medical Center - Tufts University School of Medicine , Boston , MA , USA.
b Department of Medical Oncology , Northwell Health Cancer Institute , New York , NY , USA.
Expert Opin Pharmacother. 2019 Mar;20(4):399-409. doi: 10.1080/14656566.2018.1560422. Epub 2019 Jan 16.
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which is converted to 5FU by a series of reactions catalyzed by different enzymes, the last of the enzymes being thymidine phosphorylase (TP). TP is found to be elevated in tumor cells in comparison to normal cells, which consequently tumor-localizes the production of 5-FU, thereby limiting its systemic toxicity. Today, capecitabine is extensively used for the treatment of many solid malignancies, with a particular focus in breast and gastrointestinal tumors, but also in pancreatic cancer. Areas covered: This review summarizes the pharmacology and the clinical evidence relevant to the use of capecitabine in the treatment of pancreas cancer. The authors provide, furthermore, provide their expert perspectives on its use. Expert opinion: Capecitabine has the advantage over other therapeutics in so much that it has both convenient oral administration and a favorable toxicity profile. Current data has promised the use of capecitabine in all stages of pancreatic cancer. However, predictive markers for outcome and toxicity remain to be validated.
卡培他滨是 5-氟尿嘧啶（5-FU）的口服前体药物，它在一系列由不同酶催化的反应中转化为 5FU，最后一种酶是胸苷磷酸化酶（TP）。与正常细胞相比，TP 在肿瘤细胞中升高，这使得 5-FU 在肿瘤部位产生，从而限制了其全身毒性。如今，卡培他滨被广泛用于治疗许多实体恶性肿瘤，特别是乳腺癌和胃肠道肿瘤，但也用于胰腺癌。涵盖领域：这篇综述总结了卡培他滨在胰腺癌治疗中的药理学和临床证据。作者还提供了他们对其使用的专家观点。专家意见：卡培他滨的优势在于它具有方便的口服给药和良好的毒性特征。目前的数据已经承诺在胰腺癌的所有阶段使用卡培他滨。然而，预测疗效和毒性的标志物仍有待验证。
